鼻咽癌VMAT与IMRT生活质量及生存结局比较
结果显示两组3年局部区域无复发生存、无远处转移生存、无失败生存和总生存率均无显著差异(p>0.05),生活质量变化模式相似,各时间点所有生活质量量表均无统计学或临床显著差异。
要点
- VMAT与IMRT组3年生存各指标均无显著差异(p>0.05)
- 两组生活质量变化模式相似,各时间点量表无显著差异
- 放疗后1年两组总体生活质量和社会功能改善,但吞咽、味觉、张口、口干等症状加重
核心结论
- VMAT与IMRT治疗鼻咽癌的肿瘤控制、生存及生活质量变化相容。
研究设计与样本
- 采用EORTC QLQ-C30和HN35问卷在放疗前、放疗42.4 Gy(20次)、放疗后3个月和12个月四个时间点前瞻性评估生活质量。
主要发现
- VMAT组3年局部区域无复发生存率96.6%、无远处转移生存率89.4%、无失败生存率86.1%、总生存率87.4%,IMRT组分别为91.4%、90.0%、79.8%、91.3%(p>0.05)。
- 两组生活质量变化模式相似,各时间点所有生活质量量表均无统计学或临床显著差异。
- 与放疗前相比,放疗后1年两组总体生活质量和社会功能有统计学(p<0.05)和临床(平均分差异≥10)改善,但吞咽、味觉/嗅觉、张口、口干和唾液粘稠等头颈部症状结局更差。
临床怎么用
- VMAT与IMRT在鼻咽癌放疗中均可作为选择,肿瘤控制、生存和生活质量方面结果相容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To evaluate the longitudinal changes of quality of life (QoL) and survival in patients with nasopharyngeal carcinoma (NPC) treated by volumetric-modulated arc therapy (VMAT) versus intensity-modulated radiotherapy (IMRT). METHODS: One hundred and forty non-distant metastatic NPC patients treated by VMAT (n = 66) or IMRT (n = 74) with simultaneously integrated boost between March 2013 and December 2015 at a single institute were analyzed. QoL was prospectively assessed by the EORTC QLQ-C30 and HN35 questionnaires at the four time points: before RT, RT 42.4 Gy (20 fractions), and 3, 12 months after RT. RESULTS: The 3-year locoregional relapse-free survival, distant metastasis-free survival, failure-free survival, and overall survival rates were 96.6, 89.4, 86.1%, and 87.4 for the VMAT group, respectively, compared with 91.4, 90.0, 79.8, and 91.3% for the IMRT group (p value > 0.05). The pattern of QoL changes was similar between the VMAT and IMRT group. No statistically or clinically significant difference in all the QoL scales was observed between VMAT and IMRT group at each time point. Compared to before RT, we observed statistically (p<0.05) and clinically (difference of mean scores≧10) better outcome in global QoL and social functioning, but worse head and neck symptomatic outcome in swallowing, taste/smell, opening mouth, dry mouth, and sticky saliva at the time point of 1 year after RT for both groups. CONCLUSION: The study provides the evidence that the tumor control, survival and changes of QoL is compatible for NPC patients treated by VMAT versus IMRT.
引用
- Huang TL, Tsai MH, Chuang HC, et al. Quality of life and survival outcome for patients with nasopharyngeal carcinoma treated by volumetric-modulated arc therapy versus intensity-modulated radiotherapy. Radiat Oncol. 2020. PMID: 32307024. doi:10.1186/s13014-020-01532-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。